Diverse Clinical Trials
Jonathan discusses the complexities of understanding lecanumab's effectiveness, particularly in diverse populations. He emphasizes the need for a nuanced approach to clinical trials, highlighting that while the drug shows a modest effect in controlled settings, its real-world impact on patients, especially those at high risk for Alzheimer's, remains uncertain. The conversation underscores the importance of reevaluating how we approach treatments and trials in the context of diverse patient backgrounds.In this clip
From this podcast
Short Wave
How Well Does A New Alzheimer's Drug Work For Those Most At Risk?
Related Questions